Publications | USF Parkinson's Disease and Movement Disorders Center

2014

Nutt, JG, AD Siderowf, M Guttman, PN Schmidt, RA Hauser, and . 2014. “Mobility, Mood and Site of Care Impact Health Related Quality of Life in Parkinson’s Disease. Parkinsonism Relat Disord 2014;20:274-9.”. Parkinsonism Relat Disord.

Pahwa, R, KE Lyons, RA Hauser, S Fahn, J Jankovic, E Pourcher, A Hsu, M O’Connell, S Kell, and S Gupta. 2014. “Randomized Trial of IPX066, Carbidopa/Levodopa Extended Release, in Early Parkinson’s Disease. Parkinsonism Relat Disord 2014;20:142-8.”. Relat Disord.

2013

Group, Parkinson Study. 2013. “Phase II Safety, Tolerability, and Dose Selection Study of Isradipine As a Potential Disease-Modifying Intervention in Early Parkinson’s Disease (STEADY-PD). Mov Disord 2013;28:1823-31.”. Mov Disord.

Edwards, JD, RA Hauser, ML O’Connor, EG Valdes, TA Zesiewicz, and EY Uc. 2013. “Randomized Trial of Cognitive Speed of Processing Training in Parkinson Disease. Neurology 2013;81:1284-90.”. Neurology.

Stocchi, F, O Rascol, A Destee, N Hattori, RA Hauser, AE Lang, W Poewe, et al. 2013. “AFQ056 in Parkinson Patients With Levodopa-Induced Dyskinesia: 13-Week, Randomized, Dose-Finding Study. Mov Disord 2013;28:1838-46.”. Mov Disord.

Hauser, RA. 2013. “PROUD Stands Tall: Delayed-Start Studies in Parkinson’s Disease. Lancet Neurol 2013;12:728-9.”. Lancet Neurol.

Factor, SA, K Wolski, DM Togasaki, S Huyck, M Cantillon, TW Ho, RA Hauser, and E Pourcher. 2013. “Long-Term Safety and Efficacy of Preladenant in Subjects With Fluctuating Parkinson’s Disease. Mov Disord 2013;28:817-20.”. Mov Disorders.

Bajaj, N, RA Hauser, and ID Grachev. 2013. “Clinical Utility of Dopamine Transporter Single Photon Emission CT (DaT-SPECT) With (123I) Ioflupane in Diagnosis of Parkinsonian Syndromes. J Neurol Neurosurg Psychiatry 2013;84:1288-95.”. J Neurol Neurosurg Psychiatry.

Hauser, RA, A Hsu, S Kell, AJ Espay, K Sethi, M Stacy, W Ondo, M O’Connell, and S Gupta. 2013. “Extended-Release Carbidopa-Levodopa (IPX066) Compared With Immediate-Release Carbidopa-Levodopa in Patients With Parkinson’s Disease and Motor Fluctuations: A Phase 3 Randomised, Double-Blind Trial. Lancet Neurol 2013;12:346-56.”. Lancet Neurol.

Goetz, CG, GT Stebbins, KA Chung, RA Hauser, JM Miyasaki, AP Nicholas, W Poewe, et al. 2013. “Which Dyskinesia Scale Best Detects Treatment Response? Mov Disord 2013;28:341-6.”. Mov Disord.